StockData
Unicycive Therapeutics, Inc. logo

Unicycive Therapeutics, Inc. (UNCY) company profile

UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$3.57−0.13 (-3.51%)

Close on Nov 18, 2026Market cap $99.44MP/E –Yield –

About Unicycive Therapeutics

Pharmaceutical Preparations, SIC 2834

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapies for kidney diseases and other medical conditions. The company's pipeline includes two primary therapeutic candidates: oxylanthanum carbonate, a nanoparticle lanthanum-based phosphate binder designed for treating hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate under development for acute kidney injury. Unicycive operates by licensing drug technologies from other pharmaceutical entities to advance them through clinical development, regulatory approval, and commercialization. Target populations include chronic kidney disease patients suffering from elevated phosphate levels and individuals with sudden kidney injury.

The company is based in the United States and maintains its principal executive offices in Mountain View, California, having previously maintained offices in Los Altos, California. Unicycive focuses its development and regulatory initiatives primarily within the United States market while seeking partnerships with global biopharmaceutical companies for commercial distribution worldwide.

Summary of the business section of Unicycive Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Unicycive Therapeutics, Inc.
Founded
2016
Headquarters
Mountain View, CA
Address
1975 W. El Camino Real, Suite 204 94040
Phone
(650) 384-0642
Employees
21, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
GRASSI & CO., CPAs, P.C., Jericho, New York

Stock & identifiers

Ticker
UNCY
Exchange
Nasdaq
IPO date
Jul 14, 2021
Shares outstanding
28M, Aug 12, 2026
Public float
$64.31M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-10 reverse, Jun 20, 2025
SEC CIK
1766140
CUSIP
90466Y202
ISIN
US90466Y2028
FIGI
BBG01163JG34
Share class FIGI
BBG01163JH05
EIN
81-3638692

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Shalabh K. GuptaCEO, Director5,973,471
Douglas JermasekEVP, Corporate Strategy175,012
John TownsendCFO–
Pramod GuptaEVP, Pharmaceuticals and BD41,845
Meredith ManningDirector–
Sandeep LaumasDirector105,815
Sara Kenkare-MitraDirector–
Gaurav AggarwalDirector1,789,915

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsTotalvs. prior year
Shalabh Gupta, M.D.
Chief Executive Officer
$572.00K$486.20K$1.33M$2.39M-2%
Pramod Gupta, Ph.D.
Executive VP Pharmaceutical and Business Operations
$468.00K$198.90K$369.26K$1.04M-10%
Doug Jermasek
Executive VP, Corporate Strategy
$363.00K$77.14K$41.03K$481.17K-45%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 14, 2021
Offer price
$5.00
Securities offered
5,000,000
Gross proceeds
$25.00M
Exchange
Nasdaq
First trading day
Jul 12, 2021
First-day close
$5.000.0%
Lock-up ends (est.)
Jan 8, 2022

“We are offering 5,000,000 Units at an initial public offering price of $5.00 per Unit.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 30, 2026, we had 21 full-time employees”

Corporate history

Events identified from SEC filings

See a number that looks wrong?